AAN abstract
Posted: Mon Feb 22, 2010 1:28 pm
Dear all,
There are a few Alemtuzumab (Campath) abstracts being presented at the AAN conference in April.
As someone who has had their two infusions - the last being 27 months ago, it's quite comforting that the treatment effect seems to hold good for the majority of patient for at least four years after treatment.
http://www.abstracts2view.com/aan/view. ... 0L_P04.213
I now have an annual MRI and a six-monthly check-up. My last MRI (with contrast) in December 2009 showed no signs of any disease activity which fitted with the clinical assessment.
I was pleased to read that some of the Revimmune patients were also seeing similar results.
Ian
There are a few Alemtuzumab (Campath) abstracts being presented at the AAN conference in April.
As someone who has had their two infusions - the last being 27 months ago, it's quite comforting that the treatment effect seems to hold good for the majority of patient for at least four years after treatment.
http://www.abstracts2view.com/aan/view. ... 0L_P04.213
I now have an annual MRI and a six-monthly check-up. My last MRI (with contrast) in December 2009 showed no signs of any disease activity which fitted with the clinical assessment.
I was pleased to read that some of the Revimmune patients were also seeing similar results.
Ian